Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Open for Active Comparator, Parallel, Multi-center Phase II Study to Explore the Efficacy, Safety and Tolerability of BG2109 Compared With Cetrorelix During COH in Female Subjects Undergoing ART Procedures
Conditions
Interventions
BG2109
Cetrorelix
Locations
10
China
Site No5
Changsha, China
Site No7
Guangzhou, China
Site No9
Haikou, China
Site No4
Hangzhou, China
Site No8
Hohhot, China
Site No6
Linyi, China
Start Date
August 1, 2023
Primary Completion Date
June 1, 2024
Completion Date
December 1, 2024
Last Updated
July 27, 2023
NCT07404969
NCT07359703
NCT06636838
NCT06816381
NCT05994378
NCT06990685
Lead Sponsor
Bio Genuine (Shanghai) Biotech Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions